Perspective
Volume 08:06, 2025

Journal of Biomedical and Pharmaceutical Sciences

ISSN: 2952-8100

Open Access

Overcoming Blood-Brain Barrier for CNS Drug Delivery

Marcus L. Jensen*

Department of Pharmacology, University of Oslo, Norway

Introduction

The blood-brain barrier (BBB) is a formidable physiological obstacle that significantly impedes the delivery of therapeutic agents to the central nervous system (CNS) [1]. Its intricate structure, characterized by tightly packed endothelial cells and a limited passage for most molecules, necessitates innovative approaches for drug development and delivery [1].

Recent advancements have focused on various strategies to overcome these inherent limitations, exploring novel formulations and delivery mechanisms [1]. Among these, nanoparticle-based drug delivery systems have emerged as a promising avenue, designed to encapsulate and transport therapeutic payloads across the BBB [2].

Receptor-mediated transcytosis (RMT) offers another compelling strategy, leveraging the BBB's endogenous transport pathways to shuttle molecules into the brain [3]. This approach involves targeting specific receptors expressed on the BBB endothelial cells, thereby facilitating the passage of therapeutic agents [3].

Focused ultrasound (FUS) in conjunction with microbubbles has presented itself as a non-invasive method to temporarily disrupt the BBB, creating a window for enhanced drug penetration [4]. This technique holds potential for delivering a range of therapeutics, including chemotherapy drugs and gene therapies, to targeted brain regions [4].

Efflux transporters, such as P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), represent a critical barrier by actively pumping drugs out of the brain [5]. Understanding and overcoming their activity is crucial for effective CNS drug delivery [5].

The permeability of the BBB is not static and can be significantly influenced by pathological conditions, offering opportunities for targeted therapeutic interventions [6]. Diseases like stroke, neuroinflammation, and brain tumors can alter BBB integrity, which can be exploited for enhanced drug delivery [6].

Intranasal drug delivery provides an alternative route that bypasses the BBB entirely by utilizing the olfactory and trigeminal pathways to deliver drugs directly to the brain [7]. This method offers a non-invasive approach for CNS drug delivery, circumventing the challenges associated with crossing the BBB [7].

Therapeutic antibodies and larger biologics, due to their size and hydrophilic nature, face substantial challenges in crossing the BBB [8]. Strategies to enhance their brain delivery include antibody engineering and the use of nanocarriers [8].

Gene therapy delivery to the brain is also severely restricted by the BBB, necessitating specialized vector systems [9]. Viral and non-viral vector systems are being engineered to overcome these challenges and enable efficient gene delivery to neurological disorders [9].

Collectively, the dynamic nature of the BBB, encompassing tight junctions, efflux pumps, and limited transcytosis, demands innovative solutions for therapeutic delivery [10]. Emerging technologies and synergistic approaches are being developed to enhance brain drug penetration, emphasizing the importance of personalized medicine for tailored BBB delivery strategies [10].

Description

The blood-brain barrier (BBB) serves as a critical interface, meticulously regulating the passage of substances from the bloodstream into the brain. Its highly selective nature, defined by tight junctions between endothelial cells, poses a significant obstacle for the delivery of therapeutic agents to the central nervous system (CNS) [1]. This review delves into the inherent structural and functional challenges presented by the BBB, including the action of efflux transporters and enzymatic degradation processes that further limit drug entry [1].

Nanoparticle-based drug delivery systems represent a significant advancement in circumventing BBB limitations. This article explores various nanoparticle formulations, such as liposomes and polymeric nanoparticles, designed to carry therapeutic payloads across the BBB. It examines how surface modifications and the attachment of targeting ligands can facilitate receptor-mediated transcytosis, a key mechanism for BBB penetration [2].

Receptor-mediated transcytosis (RMT) offers a sophisticated strategy by harnessing the BBB's natural transport mechanisms. This paper reviews specific receptors, like the transferrin receptor (TfR) and insulin receptor (IR), which are crucial for RMT. It explores the design of drugs and carriers that can bind to these receptors, enabling their transport into the brain, while also considering challenges like receptor saturation and off-target effects [3].

Focused ultrasound (FUS) combined with microbubbles has emerged as a non-invasive technique capable of temporarily opening the BBB. This research investigates the principles behind FUS-induced BBB opening, including its mechanical effects on endothelial cells and tight junctions. It details preclinical and clinical applications for enhancing the delivery of various therapies to the brain for conditions like glioblastoma [4].

Efflux transporters, including P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), play a pivotal role in restricting drug entry into the CNS. This review focuses on the function and impact of these transporters in limiting drug efficacy and explores strategies to overcome transporter-mediated efflux, such as developing poor substrate molecules or using efflux pump inhibitors [5].

The permeability of the BBB can be dynamically altered by pathological conditions, presenting unique opportunities and challenges for drug delivery. This article investigates how diseases such as stroke and neuroinflammation affect BBB

integrity and function, and how these changes can be leveraged for more effective drug delivery to affected brain regions [6].

Intranasal drug delivery offers a distinct advantage by bypassing the BBB altogether through the olfactory and trigeminal pathways, allowing direct drug delivery to the brain. This review examines the mechanisms and benefits of intranasal administration for CNS disorders, discussing suitable drug formulations and factors influencing brain absorption [7].

Therapeutic antibodies and biologics face substantial hurdles in crossing the BBB due to their large molecular size and hydrophilic properties. This article reviews innovative strategies aimed at enhancing the brain delivery of these complex molecules, including antibody engineering for receptor-mediated transcytosis and the use of nanocarriers [8].

Gene therapy delivery to the brain is severely constrained by the BBB, requiring specialized vector systems for effective treatment. This paper explores viral and non-viral vector systems that are engineered to overcome BBB challenges for gene delivery, examining the efficiency of different viral vectors like AAV and lentivirus [9].

The inherent dynamic nature of the BBB, characterized by tight junctions, efflux pumps, and limited transcytosis, necessitates the development of innovative drug delivery solutions. This article provides a comprehensive overview of emerging technologies and strategies designed to enhance brain drug penetration, highlighting the synergistic potential of combining different approaches and the importance of personalized medicine [10].

Conclusion

The blood-brain barrier (BBB) presents a significant challenge for delivering therapeutics to the central nervous system (CNS). This review explores various strategies to overcome these limitations. Nanoparticle-based delivery systems offer a promising approach, while receptor-mediated transcytosis (RMT) leverages endogenous transport mechanisms. Focused ultrasound (FUS) provides a non-invasive method to temporarily open the BBB. Efflux transporters are another major barrier, with strategies to inhibit their activity or bypass them being explored. Pathological conditions can alter BBB integrity, creating opportunities for targeted delivery. Intranasal delivery offers a way to bypass the BBB entirely. Delivering large molecules like antibodies and genetic material also faces BBB challenges, with specific engineering and delivery systems being developed. Combining different approaches and personalizing strategies are key for effective BBB drug delivery.

Acknowledgement

None.

Conflict of Interest

None.

References

1. William M. Pardridge. "Challenges and Strategies for Drug Delivery Across the Blood–Brain Barrier." *J. Med. Chem.* 65 (2022):12903-12917.
2. Yingjie Xiang, Hongxin Guo, Daqing Li. "Nanoparticle-based drug delivery systems for the treatment of brain diseases." *Adv. Drug Deliv. Rev.* 177 (2021):113864.
3. Mei Han, Jianhui Zhang, Tingting Han. "Receptor-Mediated Transcytosis for Blood-Brain Barrier Drug Delivery." *Pharmaceutics* 15 (2023):112.
4. Javier E. R. Guedez, Ricardo P. Carvalho, Rodrigo L. Camargo. "Focused Ultrasound for Blood-Brain Barrier Opening: A Review of the State of the Art." *Int. J. Mol. Sci.* 23 (2022):9707.
5. Anna M. Kolanczyk, Igor M. P. S. Pereira, Helena van Veen. "Efflux transporters at the blood-brain barrier: role in drug delivery and therapeutic strategies." *Drug Metab. Dispos.* 49 (2021):1623-1638.
6. Alexandra A. van der Weide, Eva K. L. van der Veen, Janette M. S. Bakker. "The Blood-Brain Barrier in Neurological Diseases: A Target for Therapeutic Intervention." *Trends Pharmacol. Sci.* 44 (2023):133-147.
7. Ritu Singh, Sandeep K. Singh, Dharam V. Singh. "Intranasal Drug Delivery to the Brain: Opportunities and Challenges." *J. Control. Release* 345 (2022):216-230.
8. Wei Zhang, Jianmei Li, Yongping Li. "Antibody-Based Approaches for Blood-Brain Barrier Penetration." *Front. Immunol.* 12 (2021):715431.
9. Hao Wang, Qianqian Zhang, Xiaolin Tong. "Gene Therapy for Neurological Disorders: Challenges and Opportunities." *Mol. Ther.* 31 (2023):974-992.
10. Shuang Chen, Yan Xu, Xuan Zhang. "Emerging Strategies for Overcoming the Blood-Brain Barrier for Therapeutic Delivery." *ACS Chem. Neurosci.* 13 (2022):3070-3085.

How to cite this article: Jensen, Marcus L.. "Overcoming Blood-Brain Barrier for CNS Drug Delivery." *J Biomed Pharm Sci* 08 (2025):553.

Address for Correspondence: Marcus, L. Jensen, Department of Pharmacology, University of Oslo, Norway, E-mail: marcus.jensendft@uio.no

Received: 02-Nov-2025, Manuscript No. jbps-26-184399; **Editor assigned:** 04-Nov-2025, PreQC No. P-184399; **Reviewed:** 18-Nov-2025, QC No. Q-184399; **Revised:** 24-Nov-2025, Manuscript No. R-184399; **Published:** 29-Nov-2025, DOI: 10.37421/2952-8100.2025.8.553